Bone Marrow – Derived Mononuclear Cells

Bone Marrow – Derived Mononuclear Cells

REX-001

Autologous bone marrow-derived mononuclear cells (BM-MNCs) are extracted from the patient’s bone marrow and processed before being infused locally at the site of diseased vascular tissue in the lower limb. REX-001, contain endothelial progenitors, mesenchymal stem cells and supporting haematopoietic stem cells which potentially promote neovascularisation in patients. Whereas conventional drug therapies typically only address the symptoms of the disease, cellular therapies target the underlying cause of the disease to induce revascularisation of the affected limb, alleviating ischemia, promoting wound healing and to deliver a much improved clinical outcome.

Our first BM-MNCs therapy candidate, REX-001, consists of processed bone marrow and has been shown in clinical trials to stimulate vascular regrowth and alleviate the serious symptoms of the disease including ulceration, ischemia and improve the patient’s quality of life.